Recent Investment Analysts’ Ratings Updates for Healthpeak Properties (DOC)

Healthpeak Properties (NYSE: DOC) recently received a number of ratings updates from brokerages and research firms:

• 5/27/2026 – Healthpeak Properties had its price target raised by Scotiabank from $19.00 to $21.00. They now have a “sector perform” rating on the stock.
• 5/22/2026 – Healthpeak Properties had its price target raised by Morgan Stanley from $18.00 to $20.00. They now have an “overweight” rating on the stock.
• 5/14/2026 – Healthpeak Properties had its price target raised by Royal Bank Of Canada from $20.00 to $21.00. They now have an “outperform” rating on the stock.
• 5/13/2026 – Healthpeak Properties had its price target raised by UBS Group AG from $17.00 to $19.00. They now have a “neutral” rating on the stock.
• 5/13/2026 – Healthpeak Properties had its price target raised by Robert W. Baird from $19.00 to $21.00. They now have an “outperform” rating on the stock.
• 5/12/2026 – Healthpeak Properties had its price target raised by Citigroup Inc. from $17.50 to $20.00. They now have a “neutral” rating on the stock.
• 5/11/2026 – Healthpeak Properties was downgraded by Evercore Inc from “outperform” to “in-line”. They now have a $21.00 price target on the stock.
• 5/10/2026 – Healthpeak Properties was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/8/2026 – Healthpeak Properties was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 5/2/2026 – Healthpeak Properties was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/28/2026 – Healthpeak Properties had its price target lowered by Morgan Stanley from $21.00 to $18.00. They now have an “overweight” rating on the stock.
• 4/24/2026 – Healthpeak Properties had its “hold (c-)” rating reaffirmed by Weiss Ratings.
• 4/23/2026 – Healthpeak Properties was upgraded by Scotiabank to “hold”.
• 4/20/2026 – Healthpeak Properties is now covered by UBS Group AG. They set a “neutral” rating and a $17.00 price target on the stock.
• 4/11/2026 – Healthpeak Properties was upgraded by Wall Street Zen from “sell” to “hold”.
• 4/6/2026 – Healthpeak Properties had its price target lowered by Robert W. Baird from $20.00 to $19.00. They now have an “outperform” rating on the stock.
• 4/1/2026 – Healthpeak Properties had its price target lowered by Citigroup Inc. from $18.00 to $17.50. They now have a “neutral” rating on the stock.

Healthpeak Properties Dividend Announcement

The firm also recently announced a monthly dividend, which will be paid on Friday, June 26th. Stockholders of record on Monday, June 15th will be issued a dividend of $0.1017 per share. This represents a c) annualized dividend and a dividend yield of 6.3%. The ex-dividend date is Monday, June 15th. Healthpeak Properties’s dividend payout ratio is presently 381.25%.

Insider Activity at Healthpeak Properties

In related news, insider Scott R. Bohn sold 10,989 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $19.45, for a total value of $213,736.05. Following the transaction, the insider owned 7,636 shares in the company, valued at $148,520.20. This trade represents a 59.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.23% of the stock is owned by company insiders.

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.